TDSGF (Telo Genomics) ROC (Joel Greenblatt) %: -1,120.00% (As of Mar. 2026)


What is Telo Genomics ROC (Joel Greenblatt) %?

Telo Genomics TDSGF ROC (Joel Greenblatt) % is -1,120.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 94.34% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Telo Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,120.00%.

The historical rank and industry rank for Telo Genomics's ROC (Joel Greenblatt) % or its related term are showing as below:

TDSGF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11028.57   Med: -1557.79   Max: -475.85
Current: -2473.52

During the past 13 years, Telo Genomics's highest ROC (Joel Greenblatt) % was -475.85%. The lowest was -11028.57%. And the median was -1557.79%.

TDSGF's ROC (Joel Greenblatt) % is ranked worse than
94.34% of 212 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.815 vs TDSGF: -2473.52

Telo Genomics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -65.50% per year.


Telo Genomics  (OTCPK:TDSGF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Telo Genomics ROC (Joel Greenblatt) % Related Terms


Telo Genomics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Telo Genomics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics ROC (Joel Greenblatt) % Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,419.31 -3,971.08 -5,816.44 -5,519.44 -10,983.33

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15,706.67 -13,931.03 -11,614.81 -1,766.47 -1,120.00

TDSGF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison

For the Diagnostics & Research subindustry, Telo Genomics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Telo Genomics's ROC (Joel Greenblatt) % falls into.



Telo Genomics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.011 + 0 + 0.037) - (0.529 + 0 + -1.1102230246252E-16)
=-0.481

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.025 + 0 + 0.016) - (0.641 + 0 + -0.0010000000000001)
=-0.599

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Telo Genomics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.68/( ( (0.16 + max(-0.481, 0)) + (0.14 + max(-0.599, 0)) )/ 2 )
=-1.68/( ( 0.16 + 0.14 )/ 2 )
=-1.68/0.15
=-1,120.00 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,120.00% mean?
Telo Genomics (TDSGF) has a ROC (Joel Greenblatt) % of -1,120.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Telo Genomics and its competitors. According to the industry distribution chart, Telo Genomics ranks #200 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 94.3%.
Is Telo Genomics' ROC (Joel Greenblatt) % too high?
Telo Genomics' current ROC (Joel Greenblatt) % is -1,120.00%. Based on the distribution chart, Telo Genomics ranks #200 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Telo Genomics' ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #200 out of 212 companies for ROC (Joel Greenblatt) %. This places Telo Genomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Telo Genomics and its competitors. Telo Genomics's current ROC (Joel Greenblatt) % is -1,120.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current ROC (Joel Greenblatt) % of -1,120.00%. The current ROC (Joel Greenblatt) % is -1,120.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current ROC (Joel Greenblatt) % is -1,120.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.